Autoantibodies to nuclear valosin-containing protein-like protein: identification and characterization of systemic sclerosis-related anti-nucleolar antibodies utilizing in vitro human proteome - Matsuda, Kazuki M; Kotani, Hirohito; Yamaguchi, Kei; Ono, Chihiro; Okumura, Taishi; Ogawa, Koji; Miya, Ayako; Sato, Ayaka; Uchino, Rikako; Yumi, Murakami; Matsunaka, Hiroshi; Kono, Masanori; et al. (medRxiv, 2023)
Objectives To identify and characterize undescribed systemic sclerosis (SSc)-related autoantibodies targeting nucleolar antigens and to assess their clinical significance.Methods We conducted proteome-wide autoantibody screening (PWAS) against serum samples from SSc patients with nucleolar patterned anti-nuclear antibodies (NUC-ANAs) of specific antibodies (Abs) unknown, utilizing wet protein arrays fabricated from in vitro human proteome. Controls included SSc patients with already-known SSc-related autoantibodies, patients with other connective tissue diseases, and healthy subjects. The selection of nucleolar antigens was performed by database search in the Human Protein Atlas. The Presence of autoantibodies was certified by immunoblots, indirect immunofluorescence assays, and immunoprecipitations. Clinical assessment was conducted by retrospective review of electric medical records.Results PWAS identified autoantibodies targeting nuclear valosin-containing protein-like (NVL), DIM1 rRNA methyltransferase ribosome maturation factor (DIMT1), and telomeric repeat binding factor 1 (TERF1) as candidates. Additional measurements in disease controls revealed that only anti-NVL Abs are exclusively detected in SSc. Detection of anti-NVL Abs was reproduced by conventional assays. Anti-NVL Ab-positive cases were characterized by significantly low prevalence of diffuse skin sclerosis and interstitial lung disease, compared to SSc cases with NUC-ANAs other than anti-NVL Abs, such as anti-U3-RNP and anti-Th/To Abs.Conclusions Anti-NVL Ab is an SSc-related autoantibody associated with a unique combination of clinical features, including limited skin sclerosis and lack of lung involvement.Competing Interest StatementK Yamaguchi, T Okumura, C Ono, K Ogawa, and N Goshima were employed by ProteoBridge Corporation. T Fukasawa and A Yoshizaki belong to the Social Cooperation Program, Department of Clinical Cannabinoid Research, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, supported by Japan Cosmetic Association and Japan Federation of Medium and Small Enterprise Organizations. T Okamura belongs to the Social Cooperation Program, Department of Functional Genomics and Immunological Diseases, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, supported by Chugai Pharmaceutical Corporation.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by The University of Tokyo Ethical Committee (Approval number 0695).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.AbantibodyACAanti-centromere antibodyANAanti-nuclear antibodyARAanti-RNA polymerase III antibodyATAanti-topoisomerase I antibodyDIMT1DIM1 rRNA methyltransferase ribosome maturation factorDMdermatomyositisELISAenzyme-linked immunosorbent assayHChealthy controlNVLnuclear valosin-containing protein-likeIIFindirect immunofluorescenceILDinterstitial lung diseaseIPimmunoprecipitationIP-MSimmunoprecipitation combined with gel-free liquid chromatography-tandem mass spectrometryIPOintestinal pseudo-obstructionNUC-ANAnucleolar patterned anti-nuclear antibodyPHpulmonary hypertensionPVDFpolyvinylidene difluoridePWASproteome-wide autoantibody screeningSDS-PAGEsodium dodecyl sulfate-polyacrylamide gel electrophoresisSLEsystemic lupus erythematosusSScsystemic sclerosisTERF1telomeric repeat binding factor 1WPAwet protein arrays